表紙
市場調査レポート

心的外傷後ストレス障害 (PTSD) 治療薬の世界市場:2015〜2019年

Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 333551
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
心的外傷後ストレス障害 (PTSD) 治療薬の世界市場:2015〜2019年 Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019
出版日: 2015年06月24日 ページ情報: 英文 71 Pages
概要

心的外傷後ストレス障害 (PTSD) は何らかの外傷に曝され、感情的に衰弱した後に発症する心理学的症状です。PTSDはどの年齢にも男女問わず起こり得るものであり、治療には心理学カウンセリングが行なわれます。世界のPTSD市場は、2014〜2019年にかけCAGR1.09%で拡大すると予測されています。

当レポートでは、世界のPTSD治療薬市場について詳細に分析し、市場の動向と2015〜2019年の成長見通し、製品概要、薬剤クラス別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

第4章 市場調査方法

第5章 製品プロファイル

  • Paxil/Seroxat
  • Zoloft

第6章 イントロダクション

第7章 PTSDの概要

  • PTSDの理解
  • 病因
  • 徴候と症状
  • 診断
  • 管理
  • PTSDの自助治療
  • 疫学
  • 経済的負担

第8章 パイプライン分析

  • パイプライン製品情報

第9章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第10章 薬剤クラス別市場セグメンテーション

  • 抗鬱剤
  • 抗不安剤
  • その他

第11章 地域別セグメンテーション

第12章 購入基準

第13章 市場成長促進因子

第14章 促進因子とその影響

第15章 市場の課題

第16章 促進因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー環境

  • 競合シナリオ
  • 市場シェア調査:2014年
  • その他の将来的見込みのあるベンダー

第20章 PTSD治療薬の世界市場

第21章 主要ベンダー調査

  • GlaxoSmithKline
  • 大塚製薬株式会社
  • Pfizer

第22章 当シリーズの他のレポート

目次
Product Code: IRTNTR6225

About PTSD

PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA), PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • Otsuka Pharmaceutical

Other Prominent Vendors

  • Azevan Pharmaceuticals
  • Baylor Research Institute
  • Eli Lilly
  • Forest Laboratories
  • H. Lundbeck
  • Humanetics Pharmaceuticals
  • Marinus Pharmaceuticals
  • Nanotherapeutics
  • Neurocrine Biosciences
  • Novartis Pharmaceuticals
  • Synchroneuron
  • Tonix Pharmaceuticals

Market Driver

  • Growing Number of Accidents and Violence Worldwide
  • For a full, detailed list, view our report

Market Challenge

  • Unavailability of Standard Diagnostic Methods
  • For a full, detailed list, view our report

Market Trend

  • Rise in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

  • 05.1. Paxil/Seroxat
  • 05.2. Zoloft

06. Introduction

07. PTSD Overview

  • 07.1. Understanding the Disorder
  • 07.2. Etiology and Pathogenesis
  • 07.3. Signs and Symptoms
    • 07.3.1. Re-experiencing Symptoms
    • 07.3.2. Avoidance Symptoms
    • 07.3.3. Arousal Symptoms
  • 07.4. Diagnosis
  • 07.5. Management
    • 07.5.1. Psychotherapy
    • 07.5.2. Pharmacotherapy
  • 07.6. Self-Help Treatment of PTSD
  • 07.7. Epidemiology
  • 07.8. Economic Burden

08. Pipeline Analysis

  • 08.1. Information on Pipeline Candidates
    • 08.1.1. Brexpiprazole
    • 08.1.2. Iloperidone
    • 08.1.3. NBI-77860/GSK-561679
    • 08.1.4. At-Ease
    • 08.1.5. PRX-3140
    • 08.1.6. SNC-102
    • 08.1.7. TNX-102 SL
    • 08.1.8. Ganaxolone
    • 08.1.9. SRX251 and SRX246
    • 08.1.10. Doxazosin
    • 08.1.11. pep-EphrinA4

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Class of Drug

  • 10.1. Antidepressant Drugs
    • 10.1.1. SSRIs
    • 10.1.2. SNRIs
    • 10.1.3. Tricyclic Antidepressants
    • 10.1.4. MAO Inhibitors
  • 10.2. Anti-anxiety Drugs
    • 10.2.1. Benzodiazepines
    • 10.2.2. Beta-blockers
  • 10.3. Others
    • 10.3.1. Atypical Antipsychotics
    • 10.3.2. Anticonvulsants
    • 10.3.3. Alpha-1 Receptor Antagonists
    • 10.3.4. Alpha-2 Adrenergic Agonists

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Analysis 2014
    • 19.2.1. Pfizer
    • 19.2.2. GlaxoSmithKline
    • 19.2.3. Otsuka Pharmaceutical
  • 19.3. Other and Future Prominent Vendors

20. Global PTSD Therapeutics Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. GlaxoSmithKline
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2014
    • 21.1.4. Business Segmentation by Revenue 2013 and 2014
    • 21.1.5. Geographical Segmentation by Revenue 2014
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Otsuka Pharmaceutical
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue 2014
    • 21.2.4. Business Segmentation by Revenue 2013 and 2014
    • 21.2.5. Geographical Segmentation by Revenue 2014
    • 21.2.6. Business Strategy
    • 21.2.7. Recent Developments
    • 21.2.8. SWOT Analysis
  • 21.3. Pfizer
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2014
    • 21.3.4. Business Segmentation by Revenue 2013 and 2014
    • 21.3.5. Geographical Segmentation by Revenue 2014
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis

22. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Events Leading to PTSD
  • Exhibit 3: Treatment Options for PTSD
  • Exhibit 4: Prevalence of PTSD among Women in US
  • Exhibit 5: Global Prevalence of PTSD by Gender
  • Exhibit 6: Pipeline Portfolio of PTSD Drugs
  • Exhibit 7: Global PTSD Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 8: Segmentation of Global PTSD Therapeutics Market by Class of Drug
  • Exhibit 9: Segmentation of Global PTSD Therapeutics Market by Region 2014
  • Exhibit 10: Major Drivers of Global PTSD Therapeutics Market
  • Exhibit 11: Major Challenges in Global PTSD Therapeutics Market
  • Exhibit 12: Major Trends in Global PTSD Therapeutics Market
  • Exhibit 13: Global PTSD Therapeutics Market Analysis 2014
  • Exhibit 14: Pfizer: YoY Growth and Revenue of Zoloft 2010-2014 ($ millions)
  • Exhibit 15: Pfizer: Revenue of Zoloft by Region 2010-2014 ($ millions)
  • Exhibit 16: GlaxoSmithKline: YoY Growth and Revenue of Paxil 2010-2014 ($ millions)
  • Exhibit 17: GlaxoSmithKline: Revenue of Paxil by Region 2010-2014 ($ millions)
  • Exhibit 18: Global PTSD Therapeutics Market: Key Takeaways
  • Exhibit 19: GlaxoSmithKline: Business Segmentation by Revenue 2014
  • Exhibit 20: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 21: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
  • Exhibit 22: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
  • Exhibit 23: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 ($ millions)
  • Exhibit 24: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 26: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 27: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top